Hycamtin
What Hycamtin is used for
Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Hycamtin
- Active substance
- topotecan
- Disease area
- Ovarian Neoplasms; Uterine Cervical Neoplasms; Small Cell Lung Carcinoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01CE01
- Marketing authorisation holder
- Sandoz Pharmaceuticals d.d.
- Authorised in the EU since
- 1996
Official information
In the USA
Same active substance: Hycamtin
In India
- Topotecan: 4 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Hycamtin used for?
Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
What is the active substance in Hycamtin?
Hycamtin contains topotecan.
Who makes Hycamtin?
The EU marketing authorisation holder is Sandoz Pharmaceuticals d.d..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU